Marina Salvadores

The paper develops ORIFormer and MuSAS to predict and map human replication origins, revealing DNA sequence determinants and tissue-specific regulation through chromatin accessibility.

The paper identifies reduced IFN-I pathway activity as a driver of chemo-refractory ovarian cancer using multi-omics analysis in a clinical trial cohort.

The paper characterizes somatic mutations in human tRNA genes, showing they are mutagenesis hotspots with tumor-specific loads and can generate altered tRNA variants affecting the genetic code.

The paper identifies two global RMD signatures of mutation rate redistribution in tumors associated with RB1 and TP53 pathway alterations and cell cycle changes.

The paper estimates the prevalence of TP53-loss phenocopying events in tumors and identifies new genes like USP28 and CNOT2 that contribute to p53 pathway inactivation without TP53 mutations.

The paper identifies mutational signatures as markers of drug sensitivity in cancer cells by analyzing drug and genetic screening data.

The paper identifies mislabelled cancer cell lines using transcriptomic and epigenomic data and proposes a 'golden set' of accurately labelled cell lines for experimental use.